

Misop Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12205226/publications.pdf>

Version: 2024-02-01

128
papers

11,514
citations

44069

48
h-index

27406

106
g-index

129
all docs

129
docs citations

129
times ranked

9671
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient and in-hospital predictors of post-discharge opioid utilization: Individualizing prescribing after radical prostatectomy based on the ORIOLES initiative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 104.e9-104.e15.	1.6	4
2	Urologist Scores in the Era of the Merit-Based Incentive Payment System (MIPS). <i>Urology Practice</i> , 2022, 9, 119-125.	0.5	2
3	KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	3.9	3
4	Early initiation of salvage radiotherapy is associated with improved metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 262-262.	1.6	0
5	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	2.5	6
6	The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 481-491.	3.0	6
7	Comparison of Perioperative and Pathologic Outcomes Between Single-port and Standard Robot-assisted Radical Prostatectomy: An Analysis of a High-volume Center and the Pooled World Experience. <i>Urology</i> , 2021, 147, 223-229.	1.0	20
8	Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 463-470.	1.5	3
9	Effect of a prospective opioid reduction intervention on opioid prescribing and use after radical prostatectomy: results of the Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) Initiative. <i>BJU International</i> , 2020, 125, 426-432.	2.5	26
10	Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>European Urology</i> , 2020, 78, 360-368.	1.9	22
11	Reducing preoperative blood orders and costs for radical prostatectomy. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 219-226.	1.4	1
12	Robotic Transrectal Ultrasound Guided Prostate Biopsy. <i>IEEE Transactions on Biomedical Engineering</i> , 2019, 66, 2527-2537.	4.2	37
13	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 470-475.e1.	1.9	26
14	Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. <i>BJU International</i> , 2019, 124, 268-274.	2.5	36
15	Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. <i>Cancer</i> , 2019, 125, 391-397.	4.1	37
16	A Prospective Cohort Study of Postdischarge Opioid Practices After Radical Prostatectomy: The ORIOLES Initiative. <i>European Urology</i> , 2019, 75, 215-218.	1.9	48
17	Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case Fatality in the Atherosclerosis Risk in Communities Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 563-569.	2.5	26
18	PTEN status assessment in the Johns Hopkins active surveillance cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 176-181.	3.9	13

#	ARTICLE	IF	CITATIONS
19	Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy. <i>Journal of Urology</i> , 2019, 201, 937-942.	0.4	7
20	Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 1482-1487.	0.4	27
21	Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 158.e7-158.e12.	1.6	4
22	MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. <i>Clinical Cancer Research</i> , 2018, 24, 3668-3680.	7.0	56
23	Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. <i>Urology</i> , 2018, 115, 39-44.	1.0	75
24	Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. <i>Eur Urol</i> 2017;71:907-12. <i>European Urology</i> , 2017, 72, e11-e12.	1.9	1
25	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. <i>European Urology</i> , 2017, 71, 740-747.	1.9	256
26	The effect of limited (tertiary) Gleason pattern 5 on the new prostate cancer grade groups. <i>Human Pathology</i> , 2017, 63, 27-32.	2.0	28
27	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. <i>Journal of Urology</i> , 2017, 197, 1060-1067.	0.4	10
28	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. <i>European Urology</i> , 2017, 71, 907-912.	1.9	44
29	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. <i>European Urology</i> , 2017, 71, 697-700.	1.9	65
30	Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. <i>BJU International</i> , 2017, 119, 444-448.	2.5	13
31	Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. <i>BJU International</i> , 2017, 119, 676-683.	2.5	86
32	Geometric systematic prostate biopsy. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2017, 26, 78-85.	1.2	5
33	Call Schedule and Sleep Patterns of Urology Residents Following the 2011 ACGME Reforms. <i>Urology Practice</i> , 2016, 3, 147-152.	0.5	9
34	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. <i>Journal of Urology</i> , 2016, 196, 1436-1444.	0.4	38
35	An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers. <i>Cancer Research</i> , 2016, 76, 1055-1065.	0.9	31
36	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 496-504.	1.9	23

#	ARTICLE	IF	CITATIONS
37	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. <i>Journal of Urology</i> , 2016, 195, 337-342.	0.4	43
38	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 157-165.	1.9	206
39	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. <i>European Urology</i> , 2016, 69, 428-435.	1.9	1,039
40	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. <i>PLoS ONE</i> , 2016, 11, e0146189.	2.5	13
41	Rare Renal Incidentaloma in Pregnancy: An Unusual Primitive Neuroectodermal Tumor Presentation. <i>Urology Case Reports</i> , 2015, 3, 12-14.	0.3	3
42	Brachytherapy for prostate cancer: feasible but oncological equivalence unproven. <i>BJU International</i> , 2015, 116, 89-91.	2.5	0
43	Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified?. <i>Urology</i> , 2015, 86, 942-946.	1.0	10
44	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. <i>European Urology</i> , 2015, 67, 342-346.	1.9	47
45	Practice Patterns and Individual Variability of Surgeons Performing Radical Prostatectomy at a High Volume Academic Center. <i>Journal of Urology</i> , 2015, 193, 812-819.	0.4	14
46	Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. <i>European Urology</i> , 2015, 68, 311-316.	1.9	5
47	Variability in Medicare Utilization and Payment Among Urologists. <i>Urology</i> , 2015, 85, 1045-1051.	1.0	36
48	Reply. <i>Urology</i> , 2015, 85, 1051.	1.0	0
49	¹⁸ F-DCFPB PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	5.0	180
50	A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia. <i>Nutrition and Cancer</i> , 2015, 67, 1104-1112.	2.0	35
51	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. <i>Modern Pathology</i> , 2015, 28, 128-137.	5.5	136
52	Allogeneic versus autologous blood transfusion and survival after radical prostatectomy (CME). <i>Transfusion</i> , 2014, 54, 2168-2174.	1.6	29
53	Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. <i>Urology</i> , 2014, 84, 1434-1441.	1.0	56
54	Robotic ultrasound and needle guidance for prostate cancer management. <i>Current Opinion in Urology</i> , 2014, 24, 75-80.	1.8	27

#	ARTICLE	IF	CITATIONS
55	Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. <i>BJU International</i> , 2014, 114, E120-E129.	2.5	20
56	Identification of men with the highest risk of early disease recurrence after radical prostatectomy. <i>Prostate</i> , 2014, 74, 628-636.	2.3	24
57	Obesity and Long-Term Survival after Radical Prostatectomy. <i>Journal of Urology</i> , 2014, 192, 1100-1104.	0.4	47
58	An updated prostate cancer staging nomogram (P&artin tables) based on cases from 2006 to 2011. <i>BJU International</i> , 2013, 111, 22-29.	2.5	323
59	Expanded Criteria to Identify Men Eligible for Active Surveillance of Low Risk Prostate Cancer at Johns Hopkins: A Preliminary Analysis. <i>Journal of Urology</i> , 2013, 190, 2033-2038.	0.4	52
60	Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. <i>Prostate</i> , 2013, 73, 1673-1680.	2.3	51
61	Endocavity Ultrasound Probe Manipulators. <i>IEEE/ASME Transactions on Mechatronics</i> , 2013, 18, 914-921.	5.8	24
62	Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 589-594.	1.6	4
63	Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. <i>Urology</i> , 2013, 81, 831-836.	1.0	40
64	Adenocarcinoma of the Prostate with Gleason Score 9-10 on Core Biopsy: Correlation with Findings at Radical Prostatectomy and Prognosis. <i>Journal of Urology</i> , 2013, 190, 2068-2073.	0.4	13
65	Prostate Specific Antigen Best Practice Statement: 2009 Update. <i>Journal of Urology</i> , 2013, 189, S2-S11.	0.4	74
66	Ultrasound Probe and Needle-Guide Calibration for Robotic Ultrasound Scanning and Needle Targeting. <i>IEEE Transactions on Biomedical Engineering</i> , 2013, 60, 1728-1734.	4.2	40
67	African American Men With Very Low Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2991-2997.	1.6	220
68	Contemporaneous comparison of open vs minimally invasive radical prostatectomy for high risk prostate cancer. <i>BJU International</i> , 2013, 112, 751-757.	2.5	40
69	Radical Prostatectomy Outcome in Men 65 Years Old or Older With Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2012, 187, 1620-1625.	0.4	20
70	Contemporary Evaluation of the National Comprehensive Cancer Network Prostate Cancer Risk Classification System. <i>Urology</i> , 2012, 80, 1075-1079.	1.0	91
71	Causes of Death After Radical Prostatectomy at a Large Tertiary Center. <i>Journal of Urology</i> , 2012, 188, 798-802.	0.4	23
72	Geometric Evaluation of Systematic Transrectal Ultrasound Guided Prostate Biopsy. <i>Journal of Urology</i> , 2012, 188, 2404-2409.	0.4	54

#	ARTICLE	IF	CITATIONS
73	Optimizing the Management of High-Risk, Localized Prostate Cancer. Korean Journal of Urology, 2012, 53, 815.	1.2	3
74	Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJU International, 2012, 109, 988-993.	2.5	22
75	Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU International, 2012, 110, 1122-1128.	2.5	39
76	Definitive Therapy for Localized Prostate Cancer. , 2012, , 2771-2788.e6.		2
77	A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. Journal of Urology, 2011, 185, 1691-1697.	0.4	70
78	Robot for ultrasound-guided prostate imaging and intervention. , 2011, , .		2
79	Pelvic Lymph Node Dissection During Laparoscopic/Robotic Prostatectomy. Journal of Urology, 2011, 185, 1667-1667.	0.4	1
80	Tandem-robot Assisted Laparoscopic Radical Prostatectomy to Improve the Neurovascular Bundle Visualization: A Feasibility Study. Urology, 2011, 77, 502-506.	1.0	64
81	Imaging guidance in minimally invasive prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 343-346.	1.6	5
82	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology, 2011, 185, 869-875.	0.4	574
83	Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	2.5	36
84	Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU International, 2011, 107, 1956-1962.	2.5	97
85	Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. World Journal of Urology, 2011, 29, 11-14.	2.2	6
86	Weight Gain Is Associated with an Increased Risk of Prostate Cancer Recurrence after Prostatectomy in the PSA Era. Cancer Prevention Research, 2011, 4, 544-551.	1.5	75
87	Cigarette Smoking and Prostate Cancer Recurrence After Prostatectomy. Journal of the National Cancer Institute, 2011, 103, 835-838.	6.3	78
88	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology, 2011, 24, 1511-1520.	5.5	57
89	PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 6563-6573.	7.0	309
90	Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU International, 2010, 106, 791-795.	2.5	28

#	ARTICLE	IF	CITATIONS
91	The impact of preoperative erectile dysfunction on survival after radical prostatectomy. BJU International, 2010, 106, 1612-1617.	2.5	13
92	Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen. Urology, 2010, 76, 715-721.	1.0	55
93	Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index. Urology, 2010, 76, 553-557.	1.0	77
94	Open Radical Retropubic Prostatectomy: Technique and Outcomes. , 2010, , 105-119.		0
95	Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surgical Oncology, 2009, 18, 268-274.	1.6	29
96	Prostate Specific Antigen Best Practice Statement: 2009 Update. Journal of Urology, 2009, 182, 2232-2241.	0.4	362
97	Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy. Journal of Urology, 2009, 182, 491-498.	0.4	18
98	Progression after radical prostatectomy for men in their thirties compared to older men. BJU International, 2008, 101, 1503-1506.	2.5	36
99	Natural History of Pathologically Organ-Confined (pT2), Gleason Score 6 or Less, Prostate Cancer After Radical Prostatectomy. Urology, 2008, 72, 172-176.	1.0	73
100	Impact of Body Mass Index on Biochemical Recurrence Rates After Radical Prostatectomy: An Analysis Utilizing Propensity Score Matching. Urology, 2008, 72, 1246-1251.	1.0	48
101	Prostate Specific Antigen Versus Prostate Specific Antigen Density as a Prognosticator of Pathological Characteristics and Biochemical Recurrence Following Radical Prostatectomy. Journal of Urology, 2008, 179, 1780-1784.	0.4	30
102	Prostate Cancerâ€™Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2008, 299, 2760.	7.4	586
103	Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era. Urology, 2007, 70, 950-955.	1.0	50
104	Contemporary Evaluation of the Dâ€™Amico Risk Classification of Prostate Cancer. Urology, 2007, 70, 931-935.	1.0	111
105	Black Race Does Not Independently Predict Adverse Outcome Following Radical Retropubic Prostatectomy at a Tertiary Referral Center. Journal of Urology, 2006, 176, 515-519.	0.4	34
106	Pathological Characteristics of Prostate Cancer Detected Through Prostate Specific Antigen Based Screening. Journal of Urology, 2006, 175, 902-906.	0.4	78
107	More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology, 2006, 67, 343-348.	1.0	37
108	Viewpoint: Expanding Prostate Cancer Screening. Annals of Internal Medicine, 2006, 144, 441.	3.9	44

#	ARTICLE	IF	CITATIONS
109	SALVAGE RADIATION THERAPY FOR PROSTATE SPECIFIC ANTIGEN PROGRESSION FOLLOWING RADICAL PROSTATECTOMY: 10-YEAR OUTCOME ESTIMATES. <i>Journal of Urology</i> , 2005, 174, 1282-1286.	0.4	70
110	Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. <i>Urology</i> , 2005, 66, 156-160.	1.0	50
111	CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTS. <i>Journal of Urology</i> , 2004, 172, 910-914.	0.4	781
112	POTENCY, CONTINENCE AND COMPLICATIONS IN 3,477 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIES. <i>Journal of Urology</i> , 2004, 172, 2227-2231.	0.4	506
113	An Evaluation of the Decreasing Incidence of Positive Surgical Margins in a Large Retropubic Prostatectomy Series. <i>Journal of Urology</i> , 2004, 171, 23-26.	0.4	133
114	Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. <i>Urology</i> , 2004, 64, 723-728.	1.0	19
115	Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 2003, 169, 517-523.	0.4	691
116	Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. <i>Urology</i> , 2003, 62, 86-91.	1.0	117
117	Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. <i>Journal of Urology</i> , 2003, 169, 517-23.	0.4	271
118	A Critical Analysis of the Interpretation of Biochemical Failure in Surgically Treated Patients Using the American Society for Therapeutic Radiation and Oncology Criteria. <i>Journal of Urology</i> , 2002, 168, 1419-1422.	0.4	69
119	Nomograms for clinically localized prostate cancer. Part I: Radical prostatectomy. <i>Urologic Oncology</i> , 2002, 20, 123-130.	1.5	14
120	Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. <i>Urology</i> , 2001, 57, 1033-1037.	1.0	76
121	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. <i>Urology</i> , 2001, 58, 746-751.	1.0	71
122	ERA SPECIFIC BIOCHEMICAL RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 166, 416-419.	0.4	266
123	LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 2001, 28, 555-565.	1.8	939
124	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. <i>Journal of Urology</i> , 2001, 165, 864-866.	0.4	30
125	Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. <i>Cancer</i> , 2001, 91, 1661-1666.	4.1	62
126	The role of free prostate-specific antigen in prostate cancer detection. <i>Current Urology Reports</i> , 2000, 1, 78-82.	2.2	6

#	ARTICLE	IF	CITATIONS
127	Non-steroidal anti-androgens in prostate cancer - current treatment practice. Expert Opinion on Pharmacotherapy, 2000, 1, 443-449.	1.8	4
128	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. Journal of Urology, 2000, 164, 89-92.	0.4	56